Clinical Trials
Flex Databases is Beginning to Implement Blockchain Technology in Our IT Systems That Manage Clinical Trial Studies
The past few years have created something of a boom in the development of Blockchain technology and its emerging applications within various industries and spheres of life. Following our strategic policy of continuous improvement and the...
Clinical Trials
ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC
ZZ Biotech announced that preliminary results of RHAPSODY, the company’s Phase 2 clinical trial in acute ischemic stroke patients, were presented at the 2018 International Stroke Conference in Los Angeles. The placebo-controlled dose-escalation trial was designed...
Clinical Trials
Araclon Biotech Partners with TFS International for Their Alzheimer’s Phase II Trial
After completing a successful phase I partnership with TFS International (TFS), Araclon Biotech a Grifols company, decided to continue the partnership with TFS advancing their Alzheimer’s disease (AD) vaccine ABvac40 into phase II. The placebo-controlled phase...
Clinical Trials
Biohaven to begin clinical development of BHV-5000 to treat Rett syndrome
Biohaven Pharmaceutical Holding Company Ltd. and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. FDA has notified the Company that it may proceed with its clinical investigation of BHV-5000. Enrollment of subjects...
Clinical Trials
BioNTech Announces Results from Two More Studies Demonstrating the Benefits of Breast Cancer Subtyping Using Mammatype
BioNTech Diagnostics GmbH is announcing new results from two studies on the MammaTyper® test which were presented at the Breast Cancer Symposium in San Antonio in December.1,2 The results of these studies again demonstrate the benefits...
Clinical Trials
Adverum Biotechnologies Doses First Patient in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 for A1AT Deficiency
Adverum Biotechnologies, Inc , a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced the dosing of the first patient in the ADVANCE Phase 1/2 clinical trial of ADVM-043 for alpha-1 antitrypsin (A1AT)...
Clinical Trials
GeNeuro To Receive €12 Million Milestone Payment from Servier for Final Patient Visit in GNbAC1 CHANGE-MS Phase 2b Study
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type 1 diabetes (T1D), announced the completion of the final visit of the last patient included...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
